Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital
NCT ID: NCT05558943
Last Updated: 2025-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
750 participants
OBSERVATIONAL
2025-10-31
2030-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To describe the AML treated within the hematology department
* To optimize the management of patients with AML.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
NCT04777916
Assessing Refractoriness and Infectious Survival Events in AML
NCT06709235
Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy
NCT06891144
Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia
NCT00224614
Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain
NCT03435341
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Acute myeloblastic leukemia are the most common leukemias in adults. This pathology is very heterogeneous. It has a poor prognosis despite numerous therapeutic advances. The lack of randomized clinical trials can make certain treatment decisions difficult. In addition, patients with comorbidities or the elderly are most often excluded from these trials even though they represent a significant proportion of new diagnoses.
Objectives:
Primary objective Evaluate the overall survival of adult patients treated for AML in our hematology department at Saint-Antoine Hospital.
Secondary objectives
* Evaluate early mortality at 30 days and 60 days post-induction
* Evaluate the CR/CRi rate after induction
* Evaluate the toxicity of the treatments
* Evaluate the relapse-free survival time
* Assess the prognostic value of JC-1 at diagnosis
* Evaluate the proportion of patients eligible for intensive treatment and/or allograft
* Evaluate the side effects of the treatments undertaken
* Describe the molecular and cytogenetic characteristics of hemopathies at diagnosis and at relapse
Duration of study:
Retrospective cohort (cohort A): patients diagnosed between junuary1,2010 and May 30,2022 Prospective cohort (cohort B): patients diagnosed between June 1, 2022 and December 31, 2023. A follow-up of 2 years will be necessary after the end of treatment.
The end of follow-up is estimated at December 2025 for the entire cohort.
Data collection:
Collection of clinical and biological data in the patient's medical file via the Orbis software
Population:
Adult patients treated for AML at Saint-Antoine hospital
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with AML
* Non objection to research
Exclusion Criteria
* Acute promyelocytic leukemia (AML3)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexis GENTHON, MD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Hematology, Hospital Saint Antoine
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP211337
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.